Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

647 public trials 86 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 51 locations
View Trial Details
Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606

Conditions
B-cell Non Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +21 more
Locations
  • Start Cala Los Angeles, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • NYU Langone New York, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
View all 29 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Boca Raton Clinical Research (BRCR) Global Plantation, Florida, United States
  • Indiana University and Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Hattiesburg Clinic Hattiesburg, Mississippi, United States
View all 171 locations
View Trial Details
Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • LLC ARENSIA Exploratory Medicine Tbilisi, Georgia
  • IMSP Institute of Oncology, ARENSIA Exploratory Medicine Chisinau, Moldova
  • Hospital Beata Maria Ana Madrid, Spain
  • Hospital Fundación Jiménez Diaz Madrid, Spain
View all 17 locations
View Trial Details

Related conditions